Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. Bardia A, et al. Among authors: mukohara t. J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909. Online ahead of print. J Clin Oncol. 2024. PMID: 38652877
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.
Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Kitagawa Y, Tsuchiya M, Kitahora M, Nagayama A, Kosaka S, Asano-Niwa Y, Seki T, Ohnuki K, Suzuki A, Ono F, Futamura M, Kawazoe H, Nakamura T. Takahashi K, et al. Among authors: mukohara t. Oncologist. 2024 Feb 10:oyae015. doi: 10.1093/oncolo/oyae015. Online ahead of print. Oncologist. 2024. PMID: 38340010 Free article.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: mukohara t. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Kawabata H, Yasojima H, Tomioka N, Yoshimura K, Takano T. Masuda J, et al. Among authors: mukohara t. J Immunother Cancer. 2023 Sep;11(9):e007126. doi: 10.1136/jitc-2023-007126. J Immunother Cancer. 2023. PMID: 37709297 Free PMC article. Clinical Trial.
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T. Uematsu M, et al. Among authors: mukohara t. Melanoma Res. 2023 Dec 1;33(6):547-552. doi: 10.1097/CMR.0000000000000924. Epub 2023 Sep 4. Melanoma Res. 2023. PMID: 37696254
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial.
Funasaka C, Hanai A, Zenda S, Mori K, Fukui M, Hirano N, Shinohara R, Fuse N, Wakabayashi M, Itagaki M, Tomioka Y, Nishina M, Arai Y, Kogawa T, Ozaki Y, Nishimura M, Kobayashi T, Hara F, Takano T, Mukohara T. Funasaka C, et al. Among authors: mukohara t. Front Oncol. 2023 Jul 7;13:1216813. doi: 10.3389/fonc.2023.1216813. eCollection 2023. Front Oncol. 2023. PMID: 37483483 Free PMC article.
The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer.
Baba K, Kawamoto M, Mamishin K, Uematsu M, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakajima H, Funasaka C, Nakao T, Kondoh C, Harano K, Matsubara N, Naito Y, Hosono A, Kawasaki T, Mukohara T. Baba K, et al. Among authors: mukohara t. Cancer Med. 2023 Jun;12(11):12095-12105. doi: 10.1002/cam4.5898. Epub 2023 Apr 3. Cancer Med. 2023. PMID: 37012214 Free PMC article.
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
Tamura K, Mukohara T, Yonemori K, Kawabata Y, Nicolas X, Tanaka T, Iwata H. Tamura K, et al. Among authors: mukohara t. Breast Cancer. 2023 May;30(3):506-517. doi: 10.1007/s12282-023-01443-8. Epub 2023 Mar 29. Breast Cancer. 2023. PMID: 36977973 Free PMC article. Clinical Trial.
Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A. Shimomura A, et al. Among authors: mukohara t. Breast Cancer Res Treat. 2023 Feb;197(3):593-602. doi: 10.1007/s10549-022-06822-x. Epub 2022 Dec 9. Breast Cancer Res Treat. 2023. PMID: 36494460 Free PMC article.
93 results